Nektar Therapeutics
455 Mission Bay Blvd South
San Francisco
California
94158
United States
Tel: 415-482-5300
Website: http://www.nektar.com/
Email: iaffairs@nektar.com
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Our success is rooted in four key elements: our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners, our unique research and development pipeline of new investigational medicines in cancer and immunology, our proprietary and proven science and technology approach that fuels our discovery efforts and our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
484 articles about Nektar Therapeutics
-
Nektar Therapeutics (CA) To Announce Financial Results For The Second Quarter 2014 On Thursday, July 31, 2014, After Close Of U.S.-Based Financial Markets
7/23/2014
-
Nektar Therapeutics (CA) Stock Trading Halted Today; FDA Advisory Committee To Discuss Peripherally-Acting Opioid Receptor Antagonists
6/11/2014
-
Nektar Therapeutics (CA) Presents Positive Preclinical Data For NKTR-214, A Novel Cancer Immunotherapy, At 50th American Society of Clinical Oncology Meeting
6/2/2014
-
Nektar Therapeutics (CA) To Present At The UBS 2014 Global Healthcare Conference In New York City
5/19/2014
-
Nektar Therapeutics (CA) Appoints Ivan Gergel, M.D. As Senior Vice President, Drug Development & Chief Medical Officer
5/19/2014
-
Nektar Therapeutics (CA) Reports Financial Results For The First Quarter Of 2014
5/8/2014
-
Nektar Therapeutics (CA) To Announce Financial Results For The First Quarter 2014 On Wednesday, May 7, 2014, After Close Of U.S.-Based Financial Markets
5/2/2014
-
Nektar Therapeutics (CA) Reports Positive Preclinical Data For Two Oncology Programs At 2014 American Association for Cancer Research
4/9/2014
-
Nektar Therapeutics (CA) Reports Fourth Quarter And Year-End 2013 Financial Results
2/27/2014
-
Nektar Therapeutics (CA) To Announce Financial Results For The Fourth Quarter And Year-End Of 2013 On Wednesday, February 26, 2014, After Close Of U.S.-Based Financial Markets
2/20/2014
-
Nektar Therapeutics (CA) Prices Public Offering Of Common Stock
1/23/2014
-
Nektar Therapeutics (CA) Announces Public Offering Of 8,500,000 Shares Of Common Stock
1/23/2014
-
Nektar Therapeutics (CA) Presents Positive Clinical Data From A Phase 1 Study Of Etirinotecan Pegol (NKTR-102) In Combination With 5-Flourouracil/Leucovorin At The 2014 Gastrointestinal Cancers Symposium
1/20/2014
-
Nektar Therapeutics (CA) Release: First Subjects Dosed In Phase 1 Clinical Study Of NKTR-171, A New Peripherally-Restricted Sodium Channel Blocker To Treat Neuropathic Pain
1/14/2014
-
Nektar Therapeutics (CA) Release: Etirinotecan Pegol (NKTR-102) Passes Interim Efficacy Analysis For BEACON Pivotal Phase 3 Clinical Study In Patients With Metastatic Breast Cancer
1/14/2014
-
Nektar Therapeutics (CA)' President And CEO, Howard W. Robin, To Present At The 32nd Annual J.P. Morgan Healthcare Conference In San Francisco, CA
1/9/2014
-
Nektar Therapeutics (CA) Release: New Drug Application For Naloxegol Accepted By FDA
11/19/2013
-
Nektar Therapeutics (CA) Reports Financial Results for the Third Quarter of 2013
11/8/2013
-
Nektar Therapeutics (CA) to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
10/31/2013
-
Nektar Therapeutics (CA) and Roswell Park Cancer Institute Announce Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Second-Line Treatment in Patients with Relapsed or Refractory Small Cell Lung Cancer (SCLC)
10/24/2013